NYSEAMERICAN:SYN - Synthetic Biologics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.50
  • Forecasted Upside: 180.48 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
+0.30 (1.20%)

This chart shows the closing price for SYN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Synthetic Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYN

Analyst Price Target is $1.50
▲ +180.48% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Synthetic Biologics in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 180.48% upside from the last price of $0.53.

This chart shows the closing price for SYN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Synthetic Biologics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/12/2021Maxim GroupUpgradeHold ➝ Buy
10/2/2020Maxim GroupDowngradeBuy ➝ Hold
8/7/2020Maxim GroupInitiated CoverageBuy$1.50
6/18/2020Maxim GroupInitiated CoverageBuy$1.50
5/6/2020Alliance Global PartnersLower Price TargetBuy$2.25 ➝ $1.25
2/28/2019William BlairReiterated RatingOutperform
11/20/2018HC WainwrightReiterated RatingBuy$6.00
8/9/2018HC WainwrightReiterated RatingBuy$35.00
5/18/2018HC WainwrightReiterated RatingBuy
5/9/2018Griffin SecuritiesDowngradeBuy ➝ Hold
5/22/2017William BlairReiterated RatingOutperform$175.00
3/5/2017William BlairReiterated RatingOutperform$175.00
1/24/2017William BlairReiterated RatingOutperform$175.00
1/14/2017(FBRC)Reiterated RatingOverweight$210.00
1/6/2017(FBRC)Boost Price TargetOutperform$175.00 ➝ $210.00
11/25/2016LaurentianDowngradeBuy ➝ Speculative Buy
11/25/2016Laurentian Bank of CanadaDowngradeBuy ➝ Speculative Buy
8/31/2016Griffin SecuritiesSet Price TargetBuy$315.00 ➝ $203.00
8/25/2016BTIG ResearchInitiated CoverageBuy$175.00
8/5/2016(FBRC)Reiterated RatingBuy
(Data available from 7/23/2016 forward)
Synthetic Biologics logo
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $0.53
Low: $0.52
High: $0.54

50 Day Range

MA: $0.37
Low: $0.32
High: $0.50

52 Week Range

Now: $0.53
Low: $0.26
High: $1.70


1,050,615 shs

Average Volume

11,957,491 shs

Market Capitalization

$70.62 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Synthetic Biologics?

The following Wall Street research analysts have issued reports on Synthetic Biologics in the last twelve months: Maxim Group.
View the latest analyst ratings for SYN.

What is the current price target for Synthetic Biologics?

1 Wall Street analysts have set twelve-month price targets for Synthetic Biologics in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 180.5%. Maxim Group has the highest price target set, predicting SYN will reach $1.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $1.50 for Synthetic Biologics in the next year.
View the latest price targets for SYN.

What is the current consensus analyst rating for Synthetic Biologics?

Synthetic Biologics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYN will outperform the market and that investors should add to their positions of Synthetic Biologics.
View the latest ratings for SYN.

What other companies compete with Synthetic Biologics?

How do I contact Synthetic Biologics' investor relations team?

Synthetic Biologics' physical mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company's listed phone number is +1-734-3327800 and its investor relations email address is [email protected] The official website for Synthetic Biologics is www.syntheticbiologics.com.